Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
Retatrutide
LY3437943, Eli Lilly Triple Agonist
A GLP-1/glucagon dual receptor agonist developed by Altimmune, similar in mechanism to survodutide. In Phase 2 trials (MOMENTUM), pemvidutide demonstrated up to 15.6% weight loss at 48 weeks with notable preservation of lean body mass — a differentiating feature compared to other weight loss drugs where significant muscle loss is a concern.
An investigational triple-agonist peptide developed by Eli Lilly that targets GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 clinical trials are underway, with early results showing unprecedented weight loss efficacy.
Activates both GLP-1 and glucagon receptors. GLP-1 reduces appetite and food intake. Glucagon activation increases energy expenditure, promotes fat oxidation, and may help preserve lean mass during weight loss by shifting energy substrate utilization toward fat rather than protein catabolism.
Activates three metabolic hormone receptors: GLP-1 (appetite suppression, insulin secretion), GIP (enhanced insulin response, fat metabolism), and glucagon (increased energy expenditure, fat oxidation). The triple mechanism may produce greater weight loss than dual agonists.
- Weight management (investigational)
- MASH/NASH treatment (investigational)
- Lean mass preservation during weight loss
- Weight management (investigational)
- Type 2 diabetes (investigational)
- Metabolic syndrome (investigational)
- GI side effects (nausea, diarrhea)
- Still in clinical trials — full safety profile not established
- Potential blood sugar effects
- Injection site reactions
- Still in clinical trials — full safety profile unknown
- GI side effects (nausea, diarrhea, vomiting) reported in trials
- Not yet approved for any indication
- Long-term effects unknown
Phase 2 completed (MOMENTUM trial). Phase 2b for MASH (IMPACT trial) ongoing. Altimmune reported 15.6% weight loss at 48 weeks with lean mass preservation. Phase 3 planning underway. The lean mass preservation claim is a key differentiator if confirmed in larger trials.
Currently in Phase 3 clinical trials. Phase 2 results showed up to 24% body weight loss at 48 weeks. FDA approval timeline uncertain but potentially 2027-2028.
- Pemvidutide Phase 2 MOMENTUM trial results
2024 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.